Diagnosis and treatment of infections caused by Mycobacterium tuberculosis, M. avium and M. kansasii;Diagnostico y tratamiento de las infecciones por micobacterias en pacientes con VIH/sida

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 16, Issue SUPPL. 1, 1998, Pages 20-28

  Pulido, Federico ^a   Iribarren, José Antonio ^b   Kindelan, José María ^c   Moreno, Santiago ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Hospital Nuestra Senora de Aranzazu   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CAPREOMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DICOUMAROL; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; NEVIRAPINE; PHENYTOIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; SPARFLOXACIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

EYE TOXICITY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; STRAIN DIFFERENCE; AIDS RELATED COMPLEX; ANTIBIOTIC RESISTANCE; ATYPICAL MYCOBACTERIOSIS; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; GROWTH, DEVELOPMENT AND AGING; INCIDENCE; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM; TREATMENT FAILURE; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HUMANS; INCIDENCE; MYCOBACTERIUM; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM INFECTIONS, ATYPICAL; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0031771739     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-255.
3. Heifets LB, Good RC. Current laboratory methods for the diagnosis of tuberculosis for the diagnosis of tuberculosis. En: Bloom BR, editor. Tuberculosis: patogenesis, protection and control. Washington, DC: ASM Press, 1991; 85-110.
4. Idígoras P, Pérez-Trallero E, Alcorta M, Gutiérrez C, Muñoz-Baroja I. Rapid detection of tuberculous and non-tuberculous mycobacteria by microscopic observation of growth on Middlebrook 7H11 agar. Eur J Clin Microbiol Infect Dis 1995; 14: 6-10.
5. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Grit Care Me 1994; 149: 1.359-1.374.
6. Perriëns JH, St. Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.
7. Pulido F, Peña JM, Rubio R, Moreno S, Gonzalez J, Guijarro C et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157: 227-232.
8. Bureau of Tuberculosis Control, the New York City Department of Health. Polices and Protocols. Octubre 1997. Disponible en: URL: http://www.ci.nyc.ny.us/htmydoh/html/tb/cppcont.html (con acceso en mayo, 1998).
9. Miralles P, Moreno S, Parras F, Cosín J, Cercenado E, Ortega A et al. Tuberculosis resistente a fármacos en un hospital general. Rev Clin Esp 1996; 196: 21-23.
10. Pérez de Molino ML, Pardo F, Carballo E, Gutiérrez MC. Resistencia de Mycobacterium tuberculosis a fármacos en un área de tuberculosis endémica. Rev Esp Quimioter 1994; 7: 137-141.
11. Grupo de Estudio de Tuberculosis Resistente de Madrid. Estudio transversal multihospitalario de tuberculosis y resistencias en Madrid (octubre de 1993-abril de 1994). Med Clin (Barc) 1996; 106:1-6.
12. Grassi C. Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 (Supl. 1): 50-54.
13. Schwander S, Rusch-Gerdes S, Mateega A, lutalo T, Tugune S, Kityo C et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tuberc Lung Dis 1995; 76: 210-218.
14. Tuset M, Miró JM, Codina C, Martínez E, García F, Mallolas J et al. Interacciones de los fármacos antirretrovirales. En: Gatell JM, Clotet B, Podzamczer D, Miró JM, editores. Guía práctica del sida. Barcelona: Ediciones Masson, 1998.
15. Perez-Stable EJ, Hopewell PC. Current tuberculosis treatment regimenes. Choosing the right one for your patient. Clin Chest Med 1989; 10: 323-339.
16. Jones BE, Otaya M, Antoniskis D, Sian S, Wang F, Mercado A et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150: 1.499-1.502.
17. Pulido F, Peña JM, Rubio R, Gonzalez J, Costa JR, Vázquez JJ et al. Factores predictives del abandono del tratamiento antituberculoso en pacientes infectados por el virus de la inmunodeficiencia humana. Rev Clin Esp, 197: 163-166.
18. Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102: 164-170.
19. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med 1993; 328: 576-578.
20. Guerrero A, Cobo J, Fortún J, Navas E, Quereda C, Asensio A et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 1997; 350: 1.738-1.742.
21. Centers for Diseases Control. Multidrug-resistant tuberculosis outbreak on an HIV ward, Madrid, Spain, 1991-1995. MMWR 1996; 45: 330-333.
22. Goble M, Iseman MD, Madsen L, Waite D, Ackerson L, Horsburg R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
23. Sahai J, Gallicano K, Swick L, Tailor S, Garbes G, Seguin I et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289-293.
24. Arrizabalaga J, Camino V, Iribarren JA, Rodríguez F, Von Wichmann MA, Casas A. Utilidad de la desensibilizacián con rifampicina en el tratamiento de enfermedades producidas por micobacterias en pacientes con sida. Med Clin (Barc) 1998. En prensa.
25. Cavicchi M, Pialoux G, Carnot F, Offredo C, Romana C, Deslandes P et al. Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase. Clin Infect Dis 1995; 20: 606-610.
26. Chaisson RE, Benson CA, Dube MP et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121: 905-911.
27. th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 de septiembre de 1995.
28. Dube M, Sattler F, Torriani F, See D, Havlir D, Kemper C et al. Prevention of relapse of MAC bacteriemia in AIDS: a randomized study of clarithromycin plus clofazimine, with or without ethambutol [resumen 206]. Washington, DC: Third Conference on Retroviruses and Opportunistic Infections, 1996.
29. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart T et al. Controlled trial of clarithromycin/ethambutol with or without clofazimine for Mycobacterium avium bacteriemia in AIDS [late breaker, resumen LB17]. Washington, DC: Third Conference on Retroviruses and Opportunistic Infections, 1996.
30. Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47: 983-1.009.
31. Massur MD. Recommendations on prophylaxis and therapy for disseminated Mycobacterium aviuin complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329: 898-904.
32. Campo RE, Campo CE. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 1.233-1.238.